Indivior PLC (IZQVF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Indivior PLC (IZQVF) trades at $20.97. Indivior PLC develops, manufactures, and sells buprenorphine-based prescription drugs for opioid dependence and co-occurring disorders. Market cap: $2.89B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for IZQVF: IZQVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IZQVF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IZQVF: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Indivior PLC (IZQVF) Healthcare & Pipeline Overview
Indivior PLC specializes in buprenorphine-based treatments for opioid dependence, operating globally with a focus on addressing addiction and co-occurring disorders. Its key products, including SUBLOCADE and SUBOXONE, position it as a significant player in the specialty pharmaceutical sector, amidst increasing awareness of opioid addiction.
What Is the Investment Thesis for IZQVF?
Indivior PLC presents a focused investment opportunity within the specialty pharmaceutical sector, driven by its expertise in opioid dependence treatments. With a P/E ratio of 19.0 and a profit margin of 16.9%, the company demonstrates profitability and financial stability. The high gross margin of 80.3% indicates strong pricing power and efficient cost management. Growth catalysts include the continued adoption of SUBLOCADE and expansion into new markets. However, potential risks include competition from generic alternatives and regulatory challenges. The company's negative beta of -0.06 suggests low volatility relative to the market, potentially offering stability in uncertain times. Investors should monitor the company's pipeline development and market share gains to assess its long-term growth potential.
Based on FMP financials and quantitative analysis
IZQVF Key Highlights
Market Cap of $2.89B reflects Indivior's established position in the specialty pharmaceutical market.
- P/E Ratio of 19.0 indicates a reasonable valuation compared to earnings.
- Profit Margin of 16.9% demonstrates efficient operations and profitability.
- Gross Margin of 80.3% showcases strong pricing power and cost management.
- Beta of -0.06 suggests low volatility compared to the overall market.
Who Are IZQVF's Competitors?
IZQVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| DUTV Digital Utilities Ventures, Inc. | $0.55 | +3.46% | $1.91B | — |
| KARBF Karo Pharma AB (publ) | $5.25 | +0.00% | $1.52B | 46 |
| KKPCF Kaken Pharmaceutical Co., Ltd. | $26.00 | +0.00% | $985M | 56 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| CAMRF Camurus AB (publ) | $64.00 | +0.00% | $3.81B | 63 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
| ANIP ANI Pharmaceuticals, Inc. | $77.32 | -0.90% | $1.76B | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IZQVF's Key Strengths?
Specialized expertise in opioid dependence treatments.
- Patented drug formulations.
- Established brand reputation.
- Global distribution network.
What Are IZQVF's Weaknesses?
Reliance on buprenorphine-based therapies.
- Exposure to generic competition.
- Regulatory risks.
- Limited product diversification.
What Could Drive IZQVF Stock Higher?
Potential FDA approval for new drug formulations targeting opioid use disorder.
- Expansion of SUBLOCADE market share through increased physician adoption.
- Research collaboration with Addex Therapeutics Ltd. to develop novel therapies.
- Publication of clinical trial results for new drug candidates.
- Geographic expansion into emerging markets with high unmet needs.
What Are the Key Risks for IZQVF?
Generic erosion of key products like SUBOXONE.
- Increased competition from other pharmaceutical companies in the opioid dependence treatment market.
- Changes in regulatory policies regarding opioid prescriptions and treatment.
- Negative publicity related to opioid addiction and potential litigation.
- Dependence on buprenorphine-based therapies with limited product diversification.
What Are the Growth Opportunities for IZQVF?
- Expansion of SUBLOCADE Market Share: SUBLOCADE, Indivior's injectable buprenorphine formulation, offers a significant growth opportunity. The market for long-acting opioid dependence treatments is expanding, driven by the convenience and improved adherence offered by injectable medications. Indivior can capitalize on this trend by increasing awareness of SUBLOCADE's benefits and expanding its distribution network. The market size for long-acting opioid dependence treatments is projected to reach $3 billion by 2028, providing a substantial runway for growth.
- Development of New Formulations and Therapies: Indivior's research collaboration with Addex Therapeutics Ltd presents an opportunity to develop novel treatments for addiction and schizophrenia. By expanding its product pipeline, Indivior can diversify its revenue streams and address unmet needs in the mental health market. The market for schizophrenia treatments is estimated at $9 billion, offering a significant growth opportunity for innovative therapies.
- Geographic Expansion into Emerging Markets: Indivior has the opportunity to expand its geographic presence into emerging markets, where the need for opioid dependence treatments is growing. By entering new markets, Indivior can increase its patient base and diversify its revenue streams. The market for opioid dependence treatments in emerging markets is projected to grow at a CAGR of 8% over the next five years, presenting a compelling growth opportunity.
- Strategic Partnerships and Acquisitions: Indivior can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. By partnering with other pharmaceutical companies or acquiring complementary businesses, Indivior can accelerate its growth and strengthen its competitive position. The pharmaceutical industry is characterized by consolidation, and Indivior can leverage this trend to its advantage.
- Increased Focus on Co-occurring Disorders: Indivior can expand its focus to address co-occurring disorders, such as depression and anxiety, which often accompany opioid dependence. By developing treatments for these co-occurring conditions, Indivior can provide comprehensive care to patients and increase its revenue per patient. The market for mental health treatments is growing rapidly, driven by increasing awareness and acceptance of mental health issues.
What Are IZQVF's Competitive Advantages?
- Patented drug formulations provide exclusivity and pricing power.
- Established brand reputation in the opioid dependence treatment market.
- Specialized expertise in buprenorphine-based therapies.
- Global distribution network provides access to a wide patient base.
What Does IZQVF Do?
Indivior PLC, established in 2014 and headquartered in North Chesterfield, Virginia, is a pharmaceutical company dedicated to developing, manufacturing, and selling treatments for opioid dependence and related disorders. The company's core focus is on buprenorphine-based prescription drugs, addressing the critical need for effective solutions in the opioid addiction crisis. Indivior's product portfolio includes SUBLOCADE, an injectable formulation of buprenorphine, and SUBOXONE, a sublingual film combining buprenorphine and naloxone. These medications are designed to reduce opioid cravings and withdrawal symptoms, aiding individuals in their recovery journey. In addition to these key products, Indivior also markets SUBOXONE sublingual tablets and SUBUTEX sublingual tablets, as well as legacy products like Temgesic, Burpex, and Buprenex. Operating in approximately 40 countries, Indivior has established a global presence, striving to make its treatments accessible to patients worldwide. The company also has a research collaboration agreement with Addex Therapeutics Ltd, focusing on developing novel treatments for addiction and schizophrenia, highlighting its commitment to innovation and expanding its therapeutic pipeline.
What Products and Services Does IZQVF Offer?
- Develops buprenorphine-based prescription drugs.
- Manufactures treatments for opioid dependence.
- Sells medications for co-occurring disorders.
- Markets SUBLOCADE injection for subcutaneous use.
- Promotes SUBOXONE sublingual film and tablets.
- Offers SUBUTEX sublingual tablets.
- Sells legacy products like Temgesic, Burpex, and Buprenex.
- Engages in research collaboration with Addex Therapeutics Ltd.
How Does IZQVF Make Money?
- Develops and patents proprietary drug formulations.
- Manufactures drugs in-house or through contract manufacturers.
- Markets and sells drugs through a global distribution network.
- Generates revenue through prescription drug sales.
What Industry Does IZQVF Operate In?
Indivior PLC operates within the specialty pharmaceutical industry, specifically targeting opioid dependence and addiction. The market for opioid addiction treatments is driven by increasing awareness of the opioid crisis and growing demand for effective therapies. The industry is characterized by intense competition, with companies like ARHCF (Adapt Pharma), ASPHF (AstraZeneca PLC), DUTV (Dr. Reddy's Laboratories Ltd), KARBF (Kaken Pharmaceutical Co Ltd), and KKPCF (Kyowa Kirin Co Ltd) vying for market share. Indivior's focus on buprenorphine-based treatments positions it as a key player in this space, with opportunities for growth through innovation and market expansion.
Who Are IZQVF's Key Customers?
- Individuals suffering from opioid dependence.
- Healthcare providers who prescribe opioid dependence treatments.
- Pharmacies that dispense prescription medications.
- Hospitals and treatment centers offering addiction services.
Company Profile
Indivior PLC operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in North Chesterfield, US. The company is led by CEO Mark Crossley. IZQVF has traded publicly since 2014.
Indivior PLC (IZQVF) Valuation Context
Valued at $2.89B, IZQVF is classified as a mid-cap stock.
Key Financial Metrics
Return on assets is 21.0%, showing how much profit it generates from its asset base. IZQVF trades at a trailing price-to-earnings ratio of 18.98, below the Healthcare sector average of ~23x. Its free cash flow yield is -3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.86 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.
IZQVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's strategic direction and recovery prospects.
- Community sentiment has shifted positively, with discussions highlighting potential growth in addiction treatment markets.
- The company has made significant strides in expanding its product portfolio, which could enhance revenue streams.
- Recent developments in regulatory approvals for new treatments have bolstered market optimism about future performance.
Bear Case
- Concerns over competition in the addiction treatment space have been voiced, with some analysts questioning market share sustainability.
- Social sentiment remains mixed, with skepticism about the long-term effectiveness of current product offerings.
- Recent lawsuits and regulatory scrutiny could pose risks to the company's reputation and operational stability.
- Market perception is clouded by past performance issues, leading some investors to remain cautious despite recent positive developments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IZQVF Latest News
No recent news available for IZQVF.
IZQVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IZQVF.
Price Targets
Wall Street price target analysis for IZQVF.
IZQVF MoonshotScore
What does this score mean?
The MoonshotScore rates IZQVF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Mark Crossley
CEO
Mark Crossley serves as the CEO of Indivior PLC, leading a workforce of 1000 employees. His career spans various leadership roles within the pharmaceutical industry, bringing extensive experience in strategic planning, commercial operations, and business development. Before joining Indivior, Crossley held key positions at leading pharmaceutical companies, where he focused on driving growth and innovation. His educational background includes advanced degrees in business and science, providing a strong foundation for his leadership in the healthcare sector.
Track Record: Under Mark Crossley's leadership, Indivior PLC has focused on expanding the market share of SUBLOCADE and advancing its pipeline of new therapies. He has overseen strategic initiatives to strengthen the company's global presence and enhance its commercial capabilities. Key milestones include successful product launches and research collaborations aimed at addressing unmet needs in the treatment of opioid dependence and co-occurring disorders.
IZQVF OTC Market Information
The OTC Other tier, where Indivior PLC (IZQVF) trades, represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often do not meet the minimum financial standards required for listing on major exchanges like the NYSE or NASDAQ. This tier includes a wide range of companies, some of which may be thinly traded or have limited financial disclosure. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges due to the potential for less liquidity, greater price volatility, and limited regulatory oversight.
- OTC Tier: OTC Other
- Limited liquidity can lead to price volatility.
- Lack of regulatory oversight increases the risk of fraud or mismanagement.
- Limited financial disclosure makes it difficult to assess the company's financial health.
- Thin trading volume can make it difficult to buy or sell shares.
- Potential for delisting or suspension of trading.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements and audit reports.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Analyze the company's stock price and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established business operations in multiple countries.
- Partnership with Addex Therapeutics Ltd.
- Focus on developing treatments for opioid dependence.
- Presence in the specialty pharmaceutical market.
- Management team with experience in the pharmaceutical industry.
Common Questions About IZQVF (Healthcare)
What does Indivior PLC do?
Indivior PLC is a global pharmaceutical company specializing in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's primary products include SUBLOCADE, an injectable buprenorphine formulation, and SUBOXONE, a sublingual film combining buprenorphine and naloxone. Indivior operates in approximately 40 countries, providing treatments to individuals suffering from opioid addiction and working to address the global opioid crisis.
What do analysts say about IZQVF stock?
Analyst coverage of IZQVF is limited due to its OTC listing. However, the company's focus on the growing opioid addiction treatment market and its established presence with products like SUBLOCADE are viewed positively. Key valuation metrics include the P/E ratio of 19.0 and the gross margin of 80.3%, indicating profitability and pricing power.
What are the main risks for IZQVF?
The main risks for Indivior PLC include generic erosion of key products like SUBOXONE, increased competition from other pharmaceutical companies in the opioid dependence treatment market, and changes in regulatory policies regarding opioid prescriptions and treatment. Additionally, negative publicity related to opioid addiction and potential litigation could impact the company's reputation and financial performance. The company's dependence on buprenorphine-based therapies also poses a risk, as it limits product diversification.
What is Indivior PLC's drug pipeline status?
Indivior PLC's drug pipeline focuses on developing new treatments for opioid use disorder, addiction, and schizophrenia. The company's research collaboration with Addex Therapeutics Ltd. aims to develop novel therapies for these conditions. While specific details on clinical trial stages and upcoming catalysts are not available, investors should monitor the company's announcements regarding pipeline progress and potential FDA approvals. Successful pipeline development is crucial for Indivior's long-term growth and diversification.
What are the key growth opportunities for IZQVF in healthcare?
Indivior PLC's key growth opportunities in healthcare include expanding the market share of SUBLOCADE, developing new formulations and therapies for opioid dependence and co-occurring disorders, and expanding its geographic presence into emerging markets. The company can also pursue strategic partnerships and acquisitions to expand its product portfolio and market reach.
What are the key factors to evaluate for IZQVF?
Evaluate IZQVF on fundamentals, analyst consensus, and risk factors. P/E: 19.0x vs the S&P 500's ~20-25x. Indivior PLC presents a focused investment opportunity within the specialty pharmaceutical sector, driven by its expertise in opioid dependence treatments. Not financial advice.
How frequently does IZQVF data refresh on this page?
IZQVF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IZQVF's recent stock price performance?
Indivior PLC (IZQVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in opioid dependence treatments. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Disclosure status on OTC markets is unknown.